Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain Metastases
Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain Metastases
Active, not recruiting · NCT07491211 · Registry updated 2026-03-27Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain Metastases | Neoplasms by Site, Thoracic Neoplasms, brain disorder, bronchial neoplasm, bronchogenic carcinoma, central nervous system cancer, central nervous system disorder, lung disorder, lung neoplasm, neoplasm, nervous system disorder, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Not stated | 2026-03-27 | NCT07491211 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Fudan University | 653 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Fudan University Shanghai Cancer Center | Shanghai | China | 4 |
| Shanghai Jiao Tong University Affiliated Chest Hospital | Shanghai | China | 1 |
| Wuhan Tongji Hospital | Wuhan | China | 2 |